Thyrotropin secreting pituitary adenoma effectively treated with octreotide

Internal Medicine

Volumn 37, Issue 12, 1998, Pages 1027-1030

  Fukuda, Taku ^a   Yokoyama, Naokata ^a   Tamai, Mami ^a   Imaizumi, Misa ^a   Kimura, Hironori ^a   Tominaga, Tan ^a   Ashizawa, Kiyoto ^a   Kiriyama, Takeshi ^a   Yoshimine, Hiroyuki ^b   Ohishi, Kazunori ^b   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Somatostatin analog; Syndrome of inappropriate TSH secretion (SITSH); Tumor shrinkage

Indexed keywords

OCTREOTIDE; PROTIRELIN; SOMATOSTATIN DERIVATIVE; THYROTROPIN; THYROXINE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ENDOCRINE TUMOR; EUTHYROIDISM; FEMALE; FREE THYROXINE INDEX; HORMONE RESISTANCE; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS ADENOMA; INTRAVENOUS DRUG ADMINISTRATION; PROVOCATION TEST; RADIODIAGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THYROTROPIN RELEASE; TREATMENT OUTCOME; TUMOR REGRESSION;

EID: 0032470088     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.37.1027     Document Type: Article

References (21)

1. Wilson CB. A decade of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg 61: 814-833, 1984.
2. Mukai K. Pituitary adenomas. Immunocytochemical study of 150 tumors with clinicopathologic correlation. Cancer 52: 648-653, 1983.
3. Saeger W, Ludecke DK. Pituitary adenomas with hyperfunction of TSH. Frequency, histological classification, immunocytochemistry and ultrastructure. Virchows Arch (Pathol Anat) 394: 255-267, 1982.
4. Ilse G, Ryan N, Kovacs K, Ilse D. Calcium deposition in human pituitary adenomas studied by histology, electron microscopy, electron diffraction and X-ray spectrometry. Exp Pathol (Jena) 18: 377-388, 1980.
5. Beckers A, Abs R, Mahler C, et al. Thyrotropin-secreting pituitary adenomas; report of seven cases. J Clin Endocrinol Metab 72: 477-483, 1991.
6. Trouillas J, Girod C, Loras B, et al. The TSH secretion in the human pituitary adenomas. Pathol Res Pract 183: 596-600, 1988.
7. Greenman Y, Melmed S. Thyrotropin-secreting pituitary tumors, in: The Pituitary, Melmed S, Ed. Blackwell Science, Cambridge, 1995, p. 546-558.
8. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119: 236-240, 1993.
9. Chanson P, Warnet A. Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide. Metabolism 41: Suppl 2, 62-65, 1992.
10. Refetoff S. Resistance to thyroid hormone, in: The Thyroid, Braverman LE, Utiger RD, Eds. Lippincott-Raven, Philadelphia, 1996, p. 1032-1048.
11. Kourides IA. Inappropriate secretion of thyroid stimulating hormone. Curr Ther Endocrinol Metab 5: 48-52, 1994.
12. Kourides IA, Ridgway EC, Weintraub BD, Bigos ST, Gershengom MC, Maloof F. Thyrotropin-induced hyperthyroidism: use of alpha and beta subunit levels to identify patients with pituitary tumors. J Clin Endocrinol Metab 45: 534-543, 1977.
13. Smallridge RC. Thyrotropin-secreting pituitary tumors. Endocrinol Metab Clin North Am 16: 765-792, 1987.
14. Faglia G, Beck-Peccoz P, Piscitelli G, Medri G. Inappropriate secretion of thyrotropin by the pituitary. Horm Res 26: 79-99, 1987.
15. Tsukamoto N, Nagaya T, Kuwayama A, et al. Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly. Endocr J 41: 437-444, 1994.
16. Francis TB, Smallridge RC, Kane J, Magner JA. Octreotide changes serum thyrotropin (TSH) glycoisomer distribution as assessed by lectin chromatography in a TSH macroadenoma patient. J Clin Endocrinol Metab 77: 183-187, 1993.
17. Liebow C, Reilly C, Serrano M, Schally V. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 86: 2003-2007, 1989.
18. Buscail L, Delesque N, Esteve JP, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 91: 2315-2319, 1994.
19. Buscail L, Esteve JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92: 1580-1584, 1995.
20. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Drug therapy. Octreotide. N Engl J Med 334: 246-254, 1996.
21. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - A clinical research center study. J Clin Endocrinol Metab 80: 2768-2775, 1995 (published erratum appears in J Clin Endocrinol Metab 80: 3238, 1995).